三环和四环抗抑郁药可以提高VMAT2的活性,并拯救引起疾病的VMAT2变体
Xunan Wang1, Ilias Marmouzi1, Peter S B Finnie1
1Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, M5S 1A8, Canada.
概括
三环和四环抗抑郁药通过增强蛋白质成熟,持续上调囊泡单胺转运体2 (VMAT2) 活性. 这种VMAT2上调提供了情绪障碍和罕见的遗传疾病,如脑单胺囊运输疾病 (BMVTD) 的潜在治疗益处.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 膀单胺转运体2 (VMAT2) 对于调节大脑中的神经递质至关重要,影响情绪,认知和运动控制.
- 尽管VMAT2在神经精神病功能中起着重要作用,但它是未被充分研究的药理学标.
- 功能障碍的VMAT2涉及情绪障碍和罕见的遗传疾病,如大脑单胺囊运输疾病 (BMVTD).
研究的目的:
- 研究三环和四环抗抑郁药对VMAT2活性的影响.
- 探索小分子在治疗应用中调节VMAT2功能的潜力.
- 评估抗抑郁药对与BMVTD相关的VMAT2变体的影响.
主要方法:
- 使用内源性 (BE(2) -M17) 和异质性 (HEK293) VMAT2表达系统的基于细胞的测试.
- 服用三环和四环抗抑郁药,以评估对VMAT2活性的急性和持续影响.
- 测试了伊米普拉和米安赛林在拯救与BMVTD相关的VMAT2变体中的有效性.
主要成果:
- 三环和四环抗抑郁药急性抑制VMAT2,但通过增强蛋白质成熟,持续上调其活性.
- 在内源地表达VMAT2.2的细胞中,VMAT2上调更为明显.
- 伊米普拉明和米安赛林成功地挽救了与疾病相关的9种VMAT2变体,恢复了功能.
结论:
- 小分子,特别是三环和四环抗抑郁药,可以提高VMAT2活性,这代表了一种新的治疗策略.
- 持续的VMAT2上调可能有利于特征是减少单胺传播的疾病,包括情绪障碍和BMVTD.
- 这些发现为通过针对VMAT2.2治疗神经精神疾病开辟了新的途径.
更多相关视频
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
343
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
343
Antidepressant Drugs: Overview
413
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
413
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
236
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
236


